AcelRx Pharma up more than 8% in early trading


AcelRx Pharmaceuticals (ACRX +8.9%) enjoys investor enthusiasm today after yesterday's earnings report after the close.

Consensus estimate for 2014 revenue is $3.6M, but the company expects to earn a $5M milestone fee in Q3 from Grunenthal GmbH when it submits its marketing application to European regulators for Zalviso by mid-year.

Quick assets on hand are sufficient to fund operations through 2015.

Mutual fund ownership has grown from 25 to 123 over the past four quarters.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs